Madrigal Pharmaceuticals
Conshohocken, PA, USA
Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Job Summary: The Senior Director Global Aggregate Reporting & Risk Management Plans is a key leader responsible for providing strategic oversight and operational leadership of pharmacovigilance activities across Madrigal’s aggregate reporting and risk management plans. This individual will build and develop processes for the development, maintenance and...